{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:13:11Z","timestamp":1770833591218,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2021R1F1A1061287"],"award-info":[{"award-number":["NRF-2021R1F1A1061287"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2020R1F1A1075489"],"award-info":[{"award-number":["NRF-2020R1F1A1075489"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020704","name":"Instituto de Investigaciones Biom\u00e9dicas, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lfs.2026.124217","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:53:40Z","timestamp":1769010820000},"page":"124217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Role of miR-338-3p and miR-378a-3p as regulators in Crohn's disease pathogenesis: Potential therapeutic implications in inflammatory bowel disease"],"prefix":"10.1016","volume":"389","author":[{"given":"Ki-Uk","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Min","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunsu","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Bin","family":"Dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeongkuk","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyuwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Yong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeyoung","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Hwan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2026.124217_bb0005","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2026.124217_bb0010","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2026.124217_bb0015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ncpgasthep0528","article-title":"Mechanisms of disease: pathogenesis of Crohn\u2019s disease and ulcerative colitis","volume":"3","author":"Sartor","year":"2006","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2026.124217_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5217\/ir.2023.00080","article-title":"Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease","volume":"22","author":"Pandey","year":"2024","journal-title":"Intest. Res."},{"key":"10.1016\/j.lfs.2026.124217_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5217\/ir.2022.00007","article-title":"Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis","volume":"21","author":"Na","year":"2023","journal-title":"Intest Res."},{"key":"10.1016\/j.lfs.2026.124217_bb0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5217\/ir.2017.15.1.38","article-title":"Second Korean guidelines for the management of Crohn's disease","volume":"15","author":"Park","year":"2017","journal-title":"Intest Res."},{"key":"10.1016\/j.lfs.2026.124217_bb0035","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2026.124217_bb0040","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00535-024-02130-x","article-title":"Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from phase II and III trials","volume":"59","author":"Massironi","year":"2024","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.lfs.2026.124217_bb0045","article-title":"Management of non-response and Loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Marsal","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.lfs.2026.124217_bb0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nri2708","article-title":"Physiological and pathological roles for microRNAs in the immune system","volume":"10","author":"O\u2019Connell","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2026.124217_bb0055","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ibd\/izac122","article-title":"MiRNA-based therapies for the treatment of inflammatory bowel disease: what are we still missing?","volume":"29","author":"Innocenti","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.lfs.2026.124217_bb0060","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","article-title":"ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2026.124217_bb0065","doi-asserted-by":"crossref","DOI":"10.1099\/ijsem.0.006421","article-title":"EzBioCloud: a genome-driven database and platform for microbiome identification and discovery","volume":"74","author":"Chalita","year":"2024","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"10.1016\/j.lfs.2026.124217_bb0070","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3389\/fimmu.2019.02449","article-title":"Inhibition of miR-378a-3p by inflammation enhances IL-33 levels: a novel mechanism of Alarmin modulation in ulcerative colitis","volume":"10","author":"Dubois-Camacho","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124217_bb0075","first-page":"2807","article-title":"miR-338-3p regulates the proliferation, apoptosis and migration of SW480 cells by targeting MACC1","volume":"17","author":"Lu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.lfs.2026.124217_bb0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD","volume":"106","author":"Yanai","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.lfs.2026.124217_bb0085","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ncpgasthep0695","article-title":"Treatment with biologic therapies and the risk of cancer in patients with IBD","volume":"4","author":"Biancone","year":"2007","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2026.124217_bb0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11882-022-01048-9","article-title":"Adverse reactions to biologic medications used in allergy and immunology diseases","volume":"22","author":"Chow","year":"2022","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.lfs.2026.124217_bb0095","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.2006.103564","article-title":"Risks and benefits of biologic therapy for inflammatory bowel diseases","volume":"56","author":"D'Haens","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.lfs.2026.124217_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10051040","article-title":"Cutaneous manifestations in biological-treated inflammatory bowel disease patients: a narrative review","volume":"10","author":"Lambert","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2026.124217_bb0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2026.124217_bb0110","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2026.124217_bb0115","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lfs.2026.124217_bb0120","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.lfs.2026.124217_bb0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2026.124217_bb0130","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2026.124217_bb0135","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.lfs.2026.124217_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147991","article-title":"MicroRNAs as innovative biomarkers for inflammatory bowel disease and prediction of colorectal Cancer","volume":"23","author":"Masi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124217_bb0145","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/ibd\/izy046","article-title":"Circulating and fecal microRNAs as biomarkers for inflammatory bowel diseases","volume":"24","author":"Sch\u00f6nauen","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.lfs.2026.124217_bb0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4292\/wjgpt.v7.i1.41","article-title":"Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease","volume":"7","author":"Soubi\u00e8res","year":"2016","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2026.124217_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158751","article-title":"MicroRNAs in inflammatory bowel disease and its complications","volume":"23","author":"Krishnachaitanya","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124217_bb0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/ibd\/izy279","article-title":"miR-206 as a biomarker for response to Mesalamine treatment in ulcerative colitis","volume":"25","author":"Minacapelli","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.lfs.2026.124217_bb0165","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000560","article-title":"ABX464 (Obefazimod) upregulates miR-124 to reduce Proinflammatory markers in inflammatory bowel diseases","volume":"14","author":"Apolit","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.lfs.2026.124217_bb0170","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3389\/fimmu.2020.00980","article-title":"Pro-inflammatory TNF-\u03b1 and IFN-\u03b3 promote tumor growth and metastasis via induction of MACC1","volume":"11","author":"Kobelt","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124217_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/gastro\/goy010","article-title":"Early detection of ulcerative colitis-associated colorectal cancer","volume":"6","author":"Zhen","year":"2018","journal-title":"Gastroenterol. Rep. (Oxf)"},{"key":"10.1016\/j.lfs.2026.124217_bb0180","doi-asserted-by":"crossref","first-page":"82.19","DOI":"10.4049\/jimmunol.210.Supp.82.19","article-title":"Role of Bacteroides acidifaciens in gut inflammation during colitis","volume":"210","author":"Staley","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2026.124217_bb0185","article-title":"The role of Akkermansia muciniphila in inflammatory bowel disease: current knowledge and perspectives","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124217_bb0190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12929-023-00935-1","article-title":"Akkermansia muciniphila and its membrane protein ameliorates intestinal inflammatory stress and promotes epithelial wound healing via CREBH and miR-143\/145","volume":"30","author":"Wade","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.lfs.2026.124217_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.867886","article-title":"MiR-378a-3p acts as a tumor suppressor in colorectal Cancer stem-like cells and affects the expression of MALAT1 and NEAT1 lncRNAs","volume":"12","author":"Castellani","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2026.124217_bb0200","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/carcin\/bgy189","article-title":"miR-338-5p inhibits cell proliferation, colony formation, migration and cisplatin resistance in esophageal squamous cancer cells by targeting FERMT2","volume":"40","author":"Lin","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lfs.2026.124217_bb0205","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.biopha.2018.06.024","article-title":"miR-338 modulates proliferation and autophagy by PI3K\/AKT\/mTOR signaling pathway in cervical cancer","volume":"105","author":"Lu","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2026.124217_bb0210","first-page":"1662","article-title":"MiR-378a-3p acts as a tumor suppressor in gastric cancer via directly targeting RAB31 and inhibiting the hedgehog pathway proteins GLI1\/2","volume":"19","author":"Xu","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.lfs.2026.124217_bb0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jjco\/hyt181","article-title":"MicroRNA-338-3p inhibits colorectal carcinoma cell invasion and migration by targeting smoothened","volume":"44","author":"Xue","year":"2014","journal-title":"Jpn. J. Clin. Oncol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:19:37Z","timestamp":1770830377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"alternative-id":["S0024320526000251"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124217","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of miR-338-3p and miR-378a-3p as regulators in Crohn's disease pathogenesis: Potential therapeutic implications in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124217"}}